“…RET short and middle isoforms contain 16 tyrosine residues in their intracellular domains and RET long isoform has two additional tyrosines in the carboxy-terminal tail. Like other receptor tyrosine kinases, RET can activate different signaling pathways including Ras/Erk, PI3K/Akt, p38/MAPK, PLCg and c-Jun N-terminal kinase (JNK) (Worby et al, 1996;Xing et al, 1998;Chiariello et al, 1998;Trupp et al, 1999;Soler et al, 1999;Hayashi et al, 2000;Takahashi, 2001;Sariola and Saarma, 2003). Among the various tyrosine kinase of RET, it has been demonstrated that Tyr1062 is involved in the activation of Ras/Erk or PI3K/Akt pathways (Besset et al, 2000;Hayashi et al, 2000Hayashi et al, , 2001Murakami et al, 1999aMurakami et al, , 1999b and it is required for GDNF-mediated differentiation and survival of neurons (Coulpier et al, 2002;Califano et al, 2000;De Vita et al, 2000;Asai et al, 1996;Besset et al, 2000) As extension of previous work (Battaglia et al, 2009), in the present study we aimed to verify if the enhancement of GDNF production in mouse striatum following treatment with LY379268 may also induce in the nigrostriatal system a time-related activation of RET receptor and its specific intracellular signaling.…”